- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04946890
A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of MRX2843 Tablets in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is open-label, dose escalation study designed to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered MRX2843 as a single agent given daily for 28 days.
The study includes two parts, Phase I and Phase II, and is carried out in three phases. The Phase I clinical study is divided into two phases: the dose escalation study (Ia) and the expanded enrollment study (Ib). The third phase is the phase II research phase, which is designed based on phase I clinical results.
Phase Ia:Cohorts of 3 patients receive MRX2843 until dose limiting toxicity is noted (DLT). At that point cohorts will expand to 6 patients until MTD is determined.
Phase Ib/ II:According to the relevant data on safety and effectiveness, expand the enrollment of FLT3 mutation relapsed/refractory AML patients at the appropriate dose
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Junmin Li, Ph.D
- Phone Number: 13817712211
- Email: Rjlijunmin@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Junmin Li,Ph.D
-
Contact:
- Junmin Li, Ph.D
- Phone Number: 13817712211
- Email: Rjlijunmin@163.com
-
Principal Investigator:
- Junmin Li, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females age ≥ 18 years;
- Expected survival period ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
- Histopathologically documented primary or secondary AML, as defined by WHO criteria, confirmed by pathology review at treating institution, meeting at least one of the following: i. After complete remission, leukemia cells reappear in peripheral blood, or the ratio of bone marrow immature cells to bone marrow cells> 5%, or leukemia cell infiltration outside the bone marrow; ii. After standard protocol (including cytarabine and a kind of Anthracycline or anthraquinone drugs) for refractory AML patients who have not achieved complete remission after two courses of treatment;
- During the dose escalation phase, there is no need to test for FLT3 mutation status; for the expansion of the enrollment and phase II study phase, the FLT3 mutation status test results within the past 6 months will be accepted; if not, the central laboratory or research center needs to test and confirm the test Patients with FLT3 mutation status in bone marrow or whole blood. The test results show that the subject has any of the following FLT3 mutation types, and can be included in the group: FLT3 internal tandem repeat (ITD), FLT3 tyrosine kinase domain (TKD);
Laboratory inspection must meet the following standards:
- Blood routine: Under normal circumstances, the white blood cell count (WBC) ≤20×109/L; or the patient's white blood cell count (WBC)>20×109/L before using hydroxyurea or cytarabine, use for a period of time and stop the drug After 3 days, check the white blood cell count (WBC) ≤20×109/L;
- Blood coagulation function: the international standardized ratio of prothrombin time and partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN);
- Liver: If there is no clear liver metastasis, serum total bilirubin ≤1.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN; if there is clear Gilbert syndrome (Unconjugated hyperbilirubinemia), total bilirubin ≤ 3.0 ULN;
- Kidney: Serum creatinine (Scr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min (calculated according to Cockcroft-Gault formula);
- Normal or abnormal ocular retinal examination has no clinical significance;
Exclusion Criteria:
- Previously received medications targeting MerTK and/or FLT3
- Histologic diagnosis of acute promyelocytic leukemia;
- Have had other malignant tumors in the past 5 years ;
- Persistent clinically significant toxicity from prior chemotherapy that is Grade 2 or higher;
- The tumor involves the central nervous system and/or the testis;
- Active, uncontrolled infection;
- Radiation therapy within 4 weeks prior to study;
- Received systemic glucocorticoids within 14 days before the first dose ;
- Left ventricular ejection fraction ≤1 × ULN,or﹤50%. Clinically significant ECG QTc prolongation (Male: >450ms, Female: >470ms).Significant cardiac disease;
- Human immunodeficiency virus positivity;
- Active hepatitis B or C or other active liver disease;
- Women who are pregnant, lactating;
- Have a history or family history of known or suspected retinitis pigmentosa;
- Inability to swallow drugs orally, and conditions that seriously affect the absorption or pharmacokinetic parameters of the test drug;
- History of type 1 diabetes;
- Any situation that is unstable or may endanger the safety of patients and their compliance with research;
- Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the judgment of the Principal Investigator, could jeopardize patient safety or interfere with the objectives of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MRX2843 orally 80 mg/d
Participants received 80 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 21 of a 21-day cycle. |
MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
|
EXPERIMENTAL: MRX2843 orally 120 mg/d
Participants received 120 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 21 of a 21-day cycle. |
MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
|
EXPERIMENTAL: MRX2843 orally 180 mg/d
Participants received 180 mg MRX2843 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 21 of a 21-day cycle. |
MRX2843 is treated at 80mg/d, 120mg/d and 180mg/d respectively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 28 Days
|
Safety: Incidence of dose limiting toxicity (DLT)and Adverse Event (AE)
|
28 Days
|
RP2D
Time Frame: 28 Days
|
Explore the maximum tolerated dose (MTD) and phase II recommended dose (RP2D), and initially formulate a reasonable dosing plan;
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum serum concentration (Cmax)
Time Frame: 28 Days
|
Maximum serum concentration (Cmax)
|
28 Days
|
Area under the plasma concentration-time curve (AUC) from time zero to the time point of t (AUC0-tn)
Time Frame: 28 Days
|
Area under the plasma concentration-time curve (AUC) from time zero to the time point of t (AUC0-tn)
|
28 Days
|
Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-inf)
Time Frame: 28 Days
|
Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0-inf)
|
28 Days
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time Frame: 28 Days
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
|
28 Days
|
Apparent volume of distribution at equilibrium after oral administration(Vss/F)
Time Frame: 28 Days
|
Apparent volume of distribution at equilibrium after oral administration(Vss/F)
|
28 Days
|
Plasma Decay Half-Life (t1/2z)
Time Frame: 28 Days
|
Plasma Decay Half-Life (t1/2z)
|
28 Days
|
Apparent Oral Clearance (CLz/F)
Time Frame: 28 Days
|
Apparent Oral Clearance (CLz/F)
|
28 Days
|
Average plasma or serum concentration(Cav)
Time Frame: 28 Days
|
Average plasma or serum concentration(Cav)
|
28 Days
|
changes in FLT3 mutation status in plasma
Time Frame: 28 Days
|
changes in FLT3 mutation status in plasma
|
28 Days
|
Rate of Complete Remission (CR)
Time Frame: 28 Days
|
Rate of Complete Remission (CR)
|
28 Days
|
Rate of partial remission (PR)
Time Frame: 28 Days
|
Rate of partial remission (PR)
|
28 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTP-66M12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
Clinical Trials on MRX2843
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell CarcinomaUnited States